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ABSTRACT
Background The distribution of the microbial aetiology
and mortality of community-acquired pneumonia (CAP)
was investigated in relation to the clinical setting and
severity scores (pneumonia severity index (PSI) and
confusion, blood urea nitrogen, respiratory rate, blood
pressure, age (CURB-65)).
Methods 3523 patients with CAP were included (15%
outpatients, 85% inpatients). The distribution of the
microbial aetiology in relation to the clinical setting and
severity scores (PSI, CURB-65) and the relative mortality
of different aetiologies across the severity scores were
analysed.
Results The aetiology was established in 1463 patients
(42%), of whom 257 died (7%). The ranking of
aetiologies varied according to site of care, with
increasing frequency of Streptococcus pneumoniae and
mixed aetiologies and decreasing frequency of atypical
pathogens in hospitalised patients and those in ICUs. The
distribution of aetiologies according to severity scores
showed corresponding patterns; however, the severity
scores were more sensitive to Gram-negative enteric
bacilli (GNEB) and Pseudomonas aeruginosa and less
sensitive in identifying mixed aetiologies as moderate-
and high-risk conditions. Mortality rates according to
aetiology and severity scoring showed increasing
mortality rates for all pathogens except atypical
pathogens. S pneumoniae had the highest number of
deaths while GNEB, P aeruginosa, Staphylococcus
aureus and mixed aetiologies had the highest mortality
rates. Legionella pneumophila was similarly distributed
according to site of care and prognostic scores.
Conclusions CAP due to atypical bacterial pathogens is
recognised both clinically and by severity scoring as
a low-risk condition. Severity scores are more sensitive
in identifying patients with GNEB and P aeruginosa as
moderate- and high-risk aetiologies whereas mixed
aetiologies may be underestimated.
INTRODUCTION
Despite the use of many microbiological tech-
niques, in nearly 50% of cases of community-
acquired pneumonia (CAP) the aetiology is
unknown.1 Most studies show that Streptococcus
pneumoniae is the most common pathogen in CAP,
and in hospitalised patients it accounts for two-
thirds of the mortality.2 Other bacterial agents
including Haemophilus influenzae and atypical
pathogens (Mycoplasma pneumoniae, Chlamydophila
pneumoniae, Coxiella burnetii and Legionella pneumo-
phila) are described in up to 35% of CAP episodes.
In addition, viral pathogens are recognised as causes
of CAP, with influenza virus the leading viral
pathogen.1 3
Since an aetiological diagnosis of CAP is usually
unavailable, the initial empirical treatment is
usually guided by microbial patterns described for
the risk categories.4 5 In general, the guidelines for
CAP management advocate empirical antibiotic
selection on the basis of the age of the patient,
comorbidities and initial severity of the illness.6e8
Recommendations of initial antimicrobial treat-
ment according to pneumonia severity are mainly
based on the notion that the risk of adverse
outcomes including excess mortality in patients
receiving inadequate initial antimicrobial treatment
increases with pneumonia severity. However, few
studies have assessed the independent effect of the
microbial aetiology on severity scores (pneumonia
severity index (PSI) and confusion, blood urea
nitrogen, respiratory rate, blood pressure, age
(CURB-65)).9 10 This study therefore aimed to
investigate the distribution of the aetiology
according to clinical setting and severity scores (PSI
and CURB-65) and the relative mortality rates in
a large series of patients with CAP.
METHODS
Study setting and design
All consecutive adult patients attending the
Hospital Clinic in Barcelona with CAP were
prospectively studied between November 1996 and
July 2008. CAP was defined as the presence of
a new infiltrate on chest radiography together with
clinical symptoms suggestive of lower respiratory
tract infection. Exclusion criteria included: (1)
severe immunosuppression (AIDS, chemotherapy,
immunosuppressive drugs); (2) active tuberculosis;
(3) healthcare-associated pneumonia; and (4) cases
with a confirmed alternative diagnosis. Non-
hospitalised patients were visited 1e7 days after
attending the outpatient clinic.
Patient characteristics and CAP scoring systems
The following data were recorded on admission to
hospital: age, gender, current smoking, comorbid
illnesses and antimicrobial treatment prior to
hospital admission, duration of symptoms prior to
visit, clinical symptoms, physical examination,
chest x-ray pattern, blood analysis and antimicro-
bial treatment at admission. All surviving patients
were visited 30e40 days after discharge. PSI and
CURB-65 score classes were assigned according to
the authors’ original designations. Patients were
stratified into low-risk, intermediate-risk and high-
risk classes as follows: PSI score: low risk¼classes
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IeIII, intermediate risk¼class IV, high risk¼class V; CURB-65:
low risk¼classes 0e1, intermediate risk¼class 2, high risk¼
classes 3e5.
Microbiological evaluation
Microbiological examination was performed in sputum, urine,
two samples of blood and nasopharyngeal swabs. Pleural
puncture, tracheobronchial aspirates (TBAS) and bron-
choalveolar lavage (BAL) fluid, when available, were collected for
Gram and ZiehleNielsen stains and for cultures for bacterial,
fungal and mycobacterial pathogens.
The aetiology was considered definite if one of the following
criteria was met: (1) positive blood culture (in the absence of an
apparent extrapulmonary focus); (2) positive bacterial culture of
pleural fluid or transthoracic needle aspiration samples; (3)
elevated serum levels of IgM against C pneumoniae ($1:64), C
burnetii ($1:80) and M pneumoniae (any positive titre); (4)
positive urinary antigen for L pneumophila (Binax Now L pneu-
mophila urinary antigen test; Trinity Biotech, Bray, Ireland); (5)
positive urinary antigen for S pneumoniae (Binax Now S pneu-
moniae urinary antigen test; Emergo Europe, The Netherlands);
(6) bacterial growth in cultures of TBAS ($105 cfu/ml),
protected specimen brushing (PSB) ($103 cfu/ml) and BAL fluid
($104 cfu/ml); (7) seroconversion (ie, a fourfold increase in IgG
titres) for C pneumoniae and L pneumophila >1:128, C burnetii
>1:80 and respiratory viruses (influenza viruses A and B, para-
influenza viruses 1e3, respiratory syncytial virus, adenovirus);
(8) detection of antigens by immunofluorescence assay plus
virus isolation or detection by reverse transcriptase (RT)-PCR
testing for respiratory viruses (influenza viruses A and B, para-
influenza viruses 1e3, respiratory syncytial virus, adenovirus).
The aetiology of pneumonia was classified as presumptive
when a predominant microorganism was isolated from a puru-
lent sample (leucocytes >25 per high power microscopic field
and few epithelial cells <10 per high power microscopic field)
and the findings of Gram staining were compatible. For the
purpose of this study, presumptive and definitive diagnoses were
analysed together.
Statistical analysis
Categorical variables were described with counts and percent-
ages. Data for continuous variables were presented as mean (SD)
or median (IQR) where appropriate. The proportions of indi-
viduals in each of the sites of care and PSI and CURB-65 groups
diagnosed with each pathogen of interest were compared using
c2 tests. c2 tests were also used to compare the proportions of
individuals with each pathogen of interest between each pair of
site of care, PSI and CURB-65 groups, with p values adjusted
using the Bonferroni method. The k concordance coefficient was
calculated to determine agreement with risk class assignment.
The interpretation of the k index value was based on the Altman
scale (<0.20, poor; 0.21e0.40, fair; 0.41e0.60, moderate;
0.61e0.80, good; and 0.81e1.00, very good).11 All analyses were
performed with SPSS software Version 16; a two-sided p value of
<0.05 was considered statistically significant.
RESULTS
Patient characteristics and outcomes
A total of 3523 adult patients with CAP were studied, of whom
514 (14.6%) were outpatients. The mean (SD) age was 65.5
(18.7) years (range 18e102); 2166 patients (62%) were aged
$65 years. The main clinical characteristics and radiological
findings of the study population are shown in table 1.
A total of 769 patients (22.4%) had received antimicrobial
treatment prior to hospital admission. One-month mortality
was 7% (n¼257).
The distribution of groups by severity scores (PSI, CURB-65)
and by site of care is shown in table 2. On admission, both scores
placed the majority of patients in the low-risk group (PSI 46%;
CURB-65 51%). Similarly, both scores classified similar propor-
tions in the high-risk group (PSI, 20%; CURB-65, 21%). Never-
theless, the accordance of risk class assignment was moderate
(k¼0.54, p<0.001): PSI classes IeIII and CURB-65 classes 0e1
(n¼1404 patients), PSI class IV and CURB-65 class 2 (n¼606)
and PSI class Vand CURB-65 classes 3e5 (n¼479). Predictions of
death were similar for both risk scores (risk group 1, 1.2% and
1.8%; risk group 2, 6.8% and 7.9%; risk group 3, 21.5% and
19.2%). However, the accordance of predictions was low
(k¼0.37, p<0.001): PSI classes IeIII and CURB-65 classes 0e1
(n¼10), PSI class IVand CURB-65 class 2 (n¼41) and PSI class V
and CURB-65 classes 3e5 (n¼114).
Diagnostic yield of applied techniques
Aetiological diagnoses were established in 1463 cases (42%).
Overall, 1463 pathogens were identified, of which 490 (34%)
were detected by sputum examination (presumptively diag-
nostic) and 973 (66%) by other techniques (definitively diag-
nostic). A single pathogen was identified in 1255 patients (86%)
and two pathogens were identified in 208 (14%). Additional
details of all applied techniques (number of performed tests and
diagnostic rates) are provided in the online supplement.
Table 1 Main characteristics of study population
Characteristic n (%)
Total number of patients 3523
Demographic data
Mean (SD) age (years) 65.5 (18.7)
Male 2218 (63)
History of smoking 963 (28)
History of alcohol abuse 581 (17)
Site of care
Outpatients 514 (15)
Inpatients 3009 (85)
Ward 2521 (72)
ICU 488 (14)
Comorbidities
Chronic respiratory disease 1599 (46)
Chronic cardiovascular disease 640 (18)
Diabetes mellitus 538 (16)
Neurological disease 555 (16)
Chronic renal disease 247 (7)
Chronic hepatic disease 154 (4)
Symptoms
Cough 2827 (81)
Sputum 2098 (61)
Dyspnoea 2327 (67)
Chest pain 1435 (41)
Fever 2824 (81)
Median (IQR) duration of symptoms (days) 4.0 (5.0)
Clinical, laboratory and radiographic findings
Median (IQR) CRP (mg/dl) 17.0 (19.3)
Median (IQR) WBC count (3109/l) 13.0 (8.3)
Median (IQR) platelet count (3109/l) 237.0 (115.0)
Alveolar pattern infiltrates 2920 (87)
Multilobar involvement ($2 lobes) 844 (24)
Pleural effusion 485 (14)
Median (IQR) length of hospital stay (days) 6.0 (6.0)
CRP, C-reactive protein; ICU, intensive care unit; WBC, white blood cells.
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Microbial aetiology of patients with CAP
The five most frequently isolated pathogens were S pneumoniae
(613 patients, 42%), atypical pathogens (C pneumoniae, M
pneumoniae, L pneumophila and C burnetii) (263 patients, 18%),
viruses (148 patients, 10%), H influenzae (70 patients, 5%) and
Pseudomonas aeruginosa (50 patients, 3%).
More than one causative agent was found in 208 patients
(14%); S pneumoniae was the most prevalent microorganism
involved in mixed infections (136/208, 65%). The most frequent
combinations among mixed infections were: two bacteria in 67
(32%), a bacterium plus a virus in 61 (29%) and a bacterium plus
an atypical pathogen in 37 (18%) (see online supplement).
Figure 1 in the online supplement illustrates the rate of
pathogen isolation during the 12-year period, showing a homo-
geneous incidence of all pathogens over time except for an
increase in S pneumoniae in 2000 and in respiratory viruses in
2004 as a result of the introduction of the pneumococcal urinary
antigen test and RT-PCR for viruses, respectively.
Overall, 333 patients had bacteraemia (S pneumoniae in 265
patients, GNEB in 14, Staphylococcus aureus in 13, H influenzae in
7, P aeruginosa in 2 and other streptococci in 32 patients). The
mortality rate associated with bacteraemic pneumococcal
pneumonia was 11%.
Microbial aetiology by site of care
The microbial aetiology was known in 32% of outpatients (514
isolates) and in 44% of inpatients (1302 isolates). The yield was
1042 of 2521 (41%) in patients treated on the ward and 260 of
488 (53%) in those treated in the ICU (table 3). The most
frequent aetiology among outpatients was the atypical path-
ogen group (36%) followed by S pneumoniae (35%), viruses and
mixed aetiologies (both 9%). In patients treated on the ward,
S pneumoniae was the most common aetiology (43%) followed
by atypical pathogens (16%), mixed aetiologies (13%) and
viruses (12%). L pneumophila was identified in 10 patients (6%).
In patients treated in the ICU the most common aetiologies
were S pneumoniae (42%), mixed aetiologies (22%) and atypical
pathogens (14%).
Microbial aetiology according to severity scores
When we analysed the aetiology by severity score groups
(tables 4 and 5), the most common pathogen was S pneumoniae
in all risk groups. In patients with low-risk scores, atypical
pathogens were second (25%) and mixed aetiologies third (13%).
The frequency of atypical pathogens decreased with severity
(15% and 8%, respectively), whereas that of mixed aetiologies
increased (15% and 17%, respectively). The frequencies of
P aeruginosa and GNEB increased in higher risk classes (3% and
8%, and 2% and 4%). Corresponding trends were found in the
distributions according to the CURB-65 severity score.
Mortality according to severity scores and microbial aetiology
Mortality rates of specific aetiologies per PSI score revealed
increasing mortality rates with increasing severity scores for
most pathogens. S pneumoniae had the highest number of deaths.
High mortality rates were observed for S aureus and GNEB (11%
and 14%, respectively) in low-risk classes. The highest mortality
rates in the group treated on the ward had GNEB (26%),
Moraxella catarrhalis (25%), S aureus (11%) and P aeruginosa
(11%). In patients treated in the ICU, S aureus (67%), GNEB
(67%), P aeruginosa (33%) and mixed aetiologies (24%) had the
highest mortalities. Again, similar patterns were found for the
CURB-65 score (tables 6 and 7).
DISCUSSION
The main findings of this study are: (1) according to the site of
care, the ranking of aetiologies varies with an increase in mixed
aetiologies and decreasing frequency of atypical pathogens from
ward to ICU; (2) the distribution of aetiologies according to
both severity scores PSI and CURB-65 revealed corresponding
patterns; (3) mortality rates by aetiology and severity scoring
showed increasing mortality rates for all pathogens except
atypical pathogens. S pneumoniae had the highest number of
deaths, whereas GNEB, P aeruginosa, S aureus, mixed aetiologies
and others had the highest mortality rates.
Several recent studies have shown that PSI and CURB-65 (and
its modification CRB-65) yield similar predictions of in-hospital
mortality in patients with CAP.12e14 Our data support this
finding, clearly showing a pattern of three risk classes of low-,
moderate- and high-risk with mortality rates of approximately
1e2%, 7e8% and 19e22%, respectively. The last figure has been
reported to be higher (30e35%) when nursing home and
bedridden patients are included.15 16 However, the severity
scores do not measure the same factors since accordance rates are
only moderate. Furthermore, it is unclear what these severity
scores truly reflect, so it seems highly relevant to study the
relation between aetiology and severity.
This study is novel in that it includes three dimensions of
analysis: the relation of aetiology to site of care as a reflection of
clinical judgement of severity and other considerations; its
Table 2 Distribution of patients and 30-day mortality in each risk class assessed using the PSI and CURB-65 scores and by site of care
Outpatients Ward ICU Total
Risk group n (%)
30-day mortality,
n (%) n (%)
30-day mortality,
n (%) n (%)
30-day mortality,
n (%) n (%)
30-day mortality,
n (%)
PSI
Low risk classes IeIII 457 (90) 1 (0.2) 1035 (41) 10 (1) 116 (24) 11 (9) 1608 (46) 22 (1)
Intermediate risk class IV 44 (9) 0 (0) 970 (39) 54 (6) 179 (37) 28 (16) 1193 (34) 82 (7)
High risk class V 8 (2) 1 (12) 508 (20) 97 (19) 192 (39) 55 (29) 708 (20) 153 (22)
CURB-65
Low risk classes 0e1 458 (89) 1 (0.2) 1197 (47) 19 (2) 151 (31) 16 (11) 1806 (51) 36 (2)
Intermediate risk class 2 48 (9) 1 (2) 785 (31) 52 (7) 144 (30) 26 (18) 977 (28) 79 (8)
High risk classes 3e5 8 (2) 0 (0) 539 (21) 90 (17) 193 (40) 52 (27) 740 (21) 142 (19)
Kappa index
Value 0.54 ND 0.52 0.40 0.39 0.37 0.54 0.39
p Value <0.001 ND <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
30-day mortality calculated as the ratio between the total number of patient deaths in each risk class and the total number of patients in each risk class multiplied by 100. PSI was not available
in 14 patients.
CURB-65, confusion, blood urea nitrogen, respiratory rate, blood pressure, age; ND, not done; PSI, pneumonia severity index.
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relation to risk classes according to both scores; and its relation
to mortality according to risk classes.
When analysing the relation of aetiology to site of care,
patients with the two atypical bacterial pathogens M pneumo-
niae and C burnetii were significantly more frequently treated as
outpatients. This is an expected finding since CAP due to
M pneumoniae and C pneumoniae are usually encountered in
younger patients without comorbidity and has a mild clinical
course.3 17 18 The severity scores equally showed that M pneu-
moniae and C burnetii were found more frequently in low-risk
patients (and a similar trend for C pneumoniae). Accordingly,
mortality was minimal in this group, regardless of the risk class.
L pneumophila was equally distributed across all sites of care
and all risk classes, with the exception of a significantly higher
frequency of patients in the moderate-risk group according to
the PSI. Since the association with severity was not obvious in
the high-risk group, this finding cannot be considered as
a consistent trend. These findings do not support those of
previous studies from the same region9 10 which show low rates
of Legionella spp. in patients with less severe disease. The equal
distribution may be partly explained by an unexpected low
overall mortality in patients with this pathogen. Indeed, the
mortality of Legionella pneumonia has decreased over the years
since the implementation of urinary antigen detection.19
Table 3 Aetiology of community-acquired pneumonia by site of care (number of patients with known
aetiology in specific site of care)
Aetiology
Outpatients
(n[161)
Ward
(n[1042)
ICU
(n[260)
Total
(n[1463) p Value
Streptococcus pneumoniae 56 (35) 447 (43) 110 (42) 613 (42) 0.150
Haemophilus influenzae 8 (5) 54 (5) 8 (3) 70 (5) 0.361
Moraxella catarrhalis 0 (0) 4 (0.4) 1 (0.4) 5 (0.3) 0.733
Atypical bacteria* y 58 (36) 168 (16) 37 (14) 263 (18) <0.001
Legionella pneumophila 10 (6) 87 (8) 21 (8) 118 (8) 0.650
Mycoplasma pneumoniae* y 27 (17) 32 (3) 6 (2) 65 (4) <0.001
Chlamydophila pneumoniae 10 (6) 32 (3) 8 (3) 50 (3) 0.117
Coxiella burnetii* y 11 (7) 17 (2) 2 (1) 30 (2) <0.001
Virusz 15 (9) 123 (12) 10 (4) 148 (10) <0.001
Staphylococcus aureus 1 (1) 18 (2) 6 (2) 25 (2) 0.429
MS 1 (1) 9 (1) 4 (2) 14 (1) 0.545
MR 0 (0) 9 (1) 2 (1) 11 (1) 0.498
GNEB 1 (1) 23 (2) 3 (1) 27 (2) 0.250
Pseudomonas aeruginosa 1 (1) 37 (4) 12 (5) 50 (3) 0.082
Mixedy z 15 (9) 135 (13) 58 (22) 208 (14) <0.001
Others 6 (4) 33 (3) 15 (6) 54 (4) 0.138
Data are expressed as n (%).
*p<0.005, outpatients vs ward.
yp<0.005, outpatients vs ICU.
zp<0.005, ward vs ICU.
GNEB, Gram-negative enteric bacilli; MR, methicillin-resistant; MS, methicillin-sensitive.
Table 4 Aetiology according to severity score (PSI) (number of patients with known aetiology in
specific risk class)
Aetiology
PSI IeIII
(n[659)
PSI IV
(n[500)
PSI V
(n[301)
Total
(n[1460) p Value
Streptococcus pneumoniae 276 (42) 205 (41) 132 (44) 613 (42) 0.728
Haemophilus influenzae 27 (4) 28 (6) 15 (5) 70 (5) 0.488
Moraxella catarrhalis 2 (0.3) 2 (0.4) 1 (0.3) 5 (0.3) 0.961
Atypical bacteria* y z 163 (25) 77 (15) 23 (8) 263 (18) <0.001
Legionella pneumophilaz 54 (8) 50 (10) 14 (5) 118 (8) 0.027
Mycoplasma pneumoniae* y 51 (8) 12 (2) 2 (1) 65 (4) <0.001
Chlamydophila pneumoniae 31 (5) 13 (3) 6 (2) 50 (3) 0.046
Coxiella burnetii* y 27 (4) 2 (0.4) 1 (0.3) 30 (2) <0.001
Virus 62 (9) 57 (11) 29 (10) 148 (10) 0.511
Staphylococcus aureus 9 (1) 10 (2) 6 (2) 25 (2) 0.651
MS 5 (1) 5 (1) 4 (1) 14 (1) 0.697
MR 4 (1) 5 (1) 2 (1) 11 (1) 0.731
GNEBy 7 (1) 9 (2) 11 (4) 27 (2) 0.022
Pseudomonas aeruginosay z 9 (1) 17 (3) 23 (8) 49 (3) <0.001
Mixed 84 (13) 73 (15) 51 (17) 208 (14) 0.217
Others 20 (3) 22 (4) 10 (3) 52 (4) 0.448
Data are expressed as n (%).
PSI was not available in three patients.
*p<0.005, PSI classes IeIII vs class IV.
yp<0.005, PSI classes IeIII vs class V.
zp<0.005, PSI class IV vs class V.
GNEB, Gram-negative enteric bacilli; MR, methicillin-resistant; MS, methicillin-sensitive; PSI, pneumonia sensitivity index.
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However, in a population with high mortality in the high-risk
group, the distribution of severity and, accordingly, of outpa-
tients and inpatients was similar.20
Patients infected with viruses were treated less frequently in
the ICU and had a very low mortality, although they were
placed equally frequently across all risk classes for both severity
scores. Since this is a somewhat heterogeneous group it should
be regarded with caution, although it agrees with previous
findings.21
As expected, all pathogens except atypical pathogens showed
increasing mortality with increasing disease severity. S pneumo-
niae had the highest number of deaths, although the relative
mortality rates were higher for S aureus, GNEB, P aeruginosa and
mixed aetiologies. It therefore seems particularly important to
identify these patients.
CAP caused by GNEB and Paeruginosa has been reported to be
associated with excess mortality.22 23 Our data confirm this
finding. Both severity scores reflected the adverse prognostic
potential of these pathogens since they occur more frequently in
moderate- and high-risk groups. Interestingly, no such association
could be found in the analysis by site of care and a corresponding
trend was only obvious for Paeruginosa. This finding may reflect
an underestimation of these pathogens or possibly that some
elderly and severely disabled patients were not admitted to the
ICU due to prognostic considerations despite a moderate to high
risk (PSI, CURB-65) and/or the presence of such aetiologies.23
Mixed aetiologies had a high mortality. Importantly, in 32.2%
of our mixed cases, bacteria were associated with other bacteria
and bacteria and viruses were found in 29.3%. In fact, de Roux
et al found a higher percentage of shock (18%) when two
Table 5 Aetiology according to severity score (CURB-65) (number of patients with known aetiology in
specific risk class)
Aetiology
CURB-65 0e1
(n[741)
CURB-65 2
(n[414)
CURB-65 3e5
(n[308)
Total
(n[1463) p Value
Streptococcus pneumoniae 291 (39) 180 (43) 142 (46) 613 (42) 0.092
Haemophilus influenzae 32 (4) 23 (6) 15 (5) 70 (5) 0.638
Moraxella catarrhalis 1 (0.1) 1 (0.2) 3 (1) 5 (0.3) 0.097
Atypical bacteria* y z 182 (25) 58 (14) 23 (7) 263 (18) <0.001
Legionella pneumophila 65 (9) 36 (9) 17 (6) 118 (8) 0.182
Mycoplasma pneumoniae* y 55 (7) 7 (2) 3 (1) 65 (4) <0.001
Chlamydophila pneumoniaey 36 (5) 12 (3) 2 (1) 50 (3) 0.002
Coxiella burnetii* y 26 (4) 3 (1) 1 (0.3) 30 (2) <0.001
Virus 81 (11) 43 (10) 24 (8) 148 (10) 0.301
Staphylococcus aureus 8 (1) 11 (3) 6 (2) 25 (2) 0.131
MS* y 2 (0.3) 7 (2) 5 (2) 14 (1) 0.024
MR 6 (1) 4 (1) 1 (0.3) 11 (1) 0.594
GNEBy z 10 (1) 4 (1) 13 (4) 27 (2) 0.002
Pseudomonas aeruginosa* y 11 (1) 18 (4) 21 (7) 50 (3) <0.001
Mixed 101 (14) 61 (15) 46 (15) 208 (14) 0.806
Others 24 (3) 15 (4) 15 (5) 54 (4) 0.441
Data are expressed as n (%).
*p<0.005, CURB-65 classes 0e1 vs 2.
yp<0.005, CURB-65 classes 0e1 vs 3e5.
zp<0.005, CURB-65 class 2 vs 3e5.
GNEB, Gram-negative enteric bacilli; MR, methicillin-resistant; MS, methicillin-sensitive.
Table 6 Mortality from community-acquired pneumonia according to aetiology and PSI risk class: number of deaths among patients with specific
aetiology (% of all deaths with specific aetiology) per PSI risk class
Aetiology PSI IeIII (n[22/1608, 1.4%) PSI IV (n[82/1193, 6.9%) PSI V (n[153/708, 21.6%) Total (n[257/3509, 7.3%)
Streptococcus pneumoniae 4/276 (1) 11/205 (5) 30/132 (23) 45/613 (7)
Haemophilus influenzae 0/27 (0) 0/28 (0) 2/15 (13) 2/70 (3)
Moraxella catarrhalis 1/2 (50) 0/2 (0) 1/1 (100) 2/5 (40)
Atypical bacteria 1/163 (1) 2/77 (3) 1/23 (4) 4/263 (2)
Legionella pneumophila 0/54 (0) 1/50 (2) 1/14 (7) 2/118 (2)
Mycoplasma pneumoniae 1/51 (2) 1/12 (8) 0/2 (0) 2/65 (3)
Chlamydophila pneumoniae 0/31 (0) 0/13 (0) 0/6 (0) 0/50 (0)
Coxiella burnetii 0/27 (0) 0/2 (0) 0/1 (0) 0/30 (0)
Virus 1/62 (2) 1/57 (2) 1/29 (3) 3/148 (2)
Staphylococcus aureus 1/9 (11) 2/10 (20) 3/6 (50) 6/25 (24)
MS 1/5 (20) 1/5 (20) 2/4 (50) 4/14 (29)
MR 0/4 (0) 1/5 (20) 1/2 (50) 2/11 (18)
GNEB 1/7 (14) 3/9 (33) 4/11 (36) 8/27 (30)
Pseudomonas aeruginosa 0/9 (0) 2/17 (12) 6/23 (26) 8/49 (16)
Mixed 2/84 (2) 5/73 (7) 15/51 (29) 22/208 (11)
Others 1/20 (5) 4/22 (18) 2/10 (20) 7/52 (13)
Unknown 10/949 (1) 52/693 (7) 88/407 (22) 150/2049 (7)
Data are expressed as number of deaths/n (%).
PSI was not available in 14 patients.
GNEB, Gram-negative enteric bacilli; MR, methicillin-resistant; MS, methicillin-sensitive; PSI, pneumonia sensitivity index.
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pyogenic bacteria were associated.24 In patients with CAP due to
mixed infections, the attending clinicians correctly recognised
this aetiology as a moderate- to high-risk condition whereas
both severity scores were less sensitive in this regard. Only PSI
showed some trend in this direction. Since severity scoring was
always present in clinical decision making, clinicians possibly
overruled the predictions made by the scores. However, it
remains unclear on what basis they did so. This issue may
require separate analysis.
Only two previous studies have tried to assess the association
of severity score and aetiology. In a limited number of patients
(n¼533) Roson et al found only S pneumoniae, GNEB, aspiration
and unknown aetiologies to be associated with increased
severity (PSI class V) and mortality. However, the analysis is
limited by small numbers with a definite aetiology (n¼283).
Dambrava et al assessed the related aetiology according to
American Thoracic Society risk stratification and found Legion-
ella spp., viruses and mixed infections to be more frequent in
high-risk groups and atypical bacterial pathogens other than
Legionella spp. in low-risk groups. Interestingly, with the
exception of the very low-risk group (previously healthy, no risk
factors) in which pneumococci were somewhat less frequently
encountered, S pneumoniae was found to an equal extent in all
risk groups. Again, the number of patients studied (n¼829) and
aetiologies defined (39%) was limited. Nevertheless, several of
these preliminary findings, although not expressively interpreted
in the context of our approach, are supported by this analysis.
Our results do not provide further clues into the intriguing
observation that both severity scoresdalbeit of overall equal
predictive potentialdobviously perform different individual
classifications. All that can be said from our analysis is that both
scores reflect the aetiology to a very similar extent, and that the
aetiology does not seem to be a factor behind the observed diver-
gent individual predictions. Since CURB-65 is far easier to apply,
our findings support the use of this score as recommended in the
most recent British Thoracic Society (BTS) guideline update.8
Our results also complement the CAP aetiological data review
recently provided by the BTS guideline update8 in two respects:
(1) they support the importance and similar frequency of
L pneumophila in any clinical setting (ambulatory, ward and
ICU); and (2) they confirm the relatively high frequency of
severe CAP mixed pneumonias, a finding of potential impor-
tance for new empirical antibiotic recommendations.
An important limitation of our study is that the microbiolog-
ical assessment was not homogeneous over time, which limits the
validity of the microbial aetiology patterns found. This is
particularly true for antigen testing. However, in studies which
include long study periods such changes may be inevitable.
In conclusion, CAP due to atypical bacterial pathogens is
recognised both clinically and by severity scoring as a low-risk
condition and L pneumophila may be correctly identified as less
severe than was thought in the past in the era of antigen testing.
GNEB (in our study mainly Escherichia coli) and P aeruginosa are
correctly identified as moderate- and high-risk pathogens,
although prognostic considerations in patients with these aeti-
ologies might lead to different treatment allocation. Mixed
aetiologies are conditions that may be underestimated by
severity scores.
The criteria behind the clinical recognition of severity in
patients with mixed aetiologies remain unclear but, if identified,
mixed aetiologies should probably be added as an independent
risk factor. The excess mortality of mixed aetiologies supports
initial empirical antimicrobial combination treatment, at least in
patients with severe CAP.
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Lung alert
Tobacco-specific carcinogen NNK has an important role
in lung cancer
Lung cancer is the leading cause of mortality in industrialised countries and 85e90% of lung
cancers are caused by cigarette smoking. DNA methyltransferase 1 (DNMT1), an enzyme
that catalyses DNA methylation, is reported to be overexpressed in patients with lung and
liver cancer who are smokers. The tobacco-specific carcinogen NNK also induces DNA
methylation. Unravelling how NNK induces DNMT1-mediated promoter hypermethylation
will improve the understanding of tobacco carcinogenesis and may provide an important link
between tobacco smoking and lung cancer.
In this study, using lung cancer as a model, animal and clinical studies were undertaken to
analyse the molecular mechanisms of DNMT1 overexpression in relation to NNK. DNMT1
overexpression strongly correlated with smoking status and poorer prognosis in patients with
lung cancer. NNK was found to increase DNMT1 protein expression and activity by
prolonging DNMT1 protein stability through AKT signalling. NNK treatment induced
DNMT1 accumulation in the nucleus and in mouse lung adenoma tissues.
These findings provide evidence for the relevance of DNMT1 overexpression in tobacco
carcinogenesis and help explain how DNMT1 overexpression may serve as a prognostic factor
in smoking-related cancer. Drugs aimed at DNMT1 depletion may prove to be a good
therapeutic strategy in the future.
< Lin RK, Hsieh YS, LinP, et al. The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor
suppressor gene hypermethylation in mice and lung cancer patients. J Clin Invest 2010;120:521e32.
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